1. CONCLUSIONS— Bezafibrate appears to have clinically important antidiabetic properties.

2. Methods:Bezafibrate pellet capsules were prepared by centrifugal granulation technology.

3. In order to observe the curative effect of bezafibrate.

4. Conclusion Bezafibrate could attenuate AS in rabbits, in which the decrease of MCP-1 protein and gene expression may be involved.

5. Randomized controlled trials should be considered to assess the utility of bezafibrate in treating patients with diabetes or in preventing diabetes in high-risk patients.

6. A post hoc analysis was used to examine the effect of bezafibrate on progression to use of oral antidiabetic medications or insulin in individuals with diabetes at baseline.